Our Recommendations
- Laboratory diagnosis of Buruli ulcer (2014)
- Diagnostic de l’ulcère de Buruli au laboratoire (2014)
- Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer) (2012)
- Buruli Ulcer Prevention of Disability (POD) (2006)
- Recognizing neglected tropical diseases through changes on the skin: a training guide for front-line health workers (2018)
New Publications
Filter
72
Featured
Recommendations
9
New Publications
3
Language
Document type
Studies & Reports
18
Guidelines
17
Videos
7
Manuals
6
Brochures
6
Fact sheets
6
Resource Platforms
5
Infographics
3
Training Material
1
App
1
Online Courses
1
Strategic & Response Plan
1
Countries / Regions
Global
12
Authors & Publishers
Publication Years
Category
Clinical Guidelines
25
Pharmacy & Technologies
4
Capacity Building
1
Public Health
1
Countries
1
Key Resources
1
MEDBOX Issue Brief no.35: The first issue brief on the NTD Toolbox contains general strategies, roadmaps, key treatment guidelines, reports, and training material on Buruli ulcer, Chagas, and Leishmaniasis.
Skin NTDs App
recommended
Recognizing neglected tropical diseseases through changes on the skin.
App for Android and IOS, free of charge. The App is available in English and French, with plans to explore translations into other languages, such as Portuguese and Spanish, to better serve diverse communities.
A patient's skin...
Website last accessed on 18.03.2023
Website last accessed on 18.03.2023
The GHO data repository is WHO's gateway to health-related statistics for its 194 Member States. It provides access to over 1000 health topics indicators.
Website last accessed on 18.03.2023
Early detection of cases is critical to complete cure with combined antibiotics. In its late stages, Buruli ulcer causes severe destruction of the skin, leading to permanent disability. #BeatNTDs
Website - last accessed on 18.03.2023
Website last accessed on 18.03.2023
Website last accessed on 18.03.2023
Buruli Ulcer Disease: Obtaining Swab Specimens for Diagnosis of M. Ulcerans Infection - Youtube video
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communities in Australia.
This course is intended to provide basic information for front-line health workers to be able to implement the recommended control measures to minimize the negative impact of Buruli ulcer on populations.
In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified:
a diagnostic test for early detection of Buruli ulcer in symptomatic patients with sufficient positive...
Key facts
Buruli ulcer is a chronic debilitating disease caused by an environmental Mycobacterium ulcerans.
At least 33 countries with tropical, subtropical and temperate climates have reported Buruli ulcer in Africa, South America and Western Pacific regions.
It often affects the skin an...
Principaux faits
L’ulcère de Buruli est une infection chronique débilitante causée par la bactérie Mycobacterium ulcerans.
L’ulcère de Buruli a été signalé dans au moins 33 pays situés dans des régions au climat tropical, subtropical ou tempéré d’Afrique, d’Amérique ...
Datos y cifras
La úlcera de Buruli es una enfermedad crónica y debilitante causada por una micobacteria ambiental: Mycobacterium ulcerans.
Al menos 33 países de clima tropical, subtropical o templado han notificado casos de úlcera de Buruli en África, América del Sur y las regiones...
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form...
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection....
A total of 18 laboratories from 13 countries participated in the four rounds of EQA: 10 laboratories from eight African endemic countries, four of which participated in all four rounds and three in three rounds. The overall results showed that the median performance of these laboratories improved ov...
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of...
